Titan Medical’s surgeon workstation
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Titan Medical (TMD) released financial results for the three and six months ended June 30, 2022
  • Titan had cash and cash equivalents of $20.2 million as of June 30, 2022, compared to $32.3 million at December 31, 2021
  • R&D expenses were $19.1 million for the six months ended June 30, 2022, compared to $17.6 million for the six months ended June 30, 2021
  • Titan Medical Inc. (TMD) was down 6.85 per cent, trading at C$0.68 per share at 12:20 pm ET

Titan Medical (TMD) released financial results for the three and six months ended June 30, 2022.

Titan had cash and cash equivalents of $20.2 million as of June 30, 2022, compared to $32.3 million at December 31, 2021.

R&D expenses were $19.1 million for the six months ended June 30, 2022, compared to $17.6 million for the six months ended June 30, 2021.

These expenses were related to the development of the Enos system and an increase in labour costs as the company continues to add the required resources to its engineering and regulatory teams.

The company plans to pursue a De Novo regulatory process for marketing authorization with the U.S. Food and Drug Administration (FDA). Utilizing the Q-Submission program, the company has engaged in ongoing dialogue with the FDA to clarify requirements to mitigate against timeline risks. The company plans to file the IDE application with the FDA mid-year 2023.

The company also recently appointed of Cary G. Vance as President and Chief Executive Officer, having previously served as CEO at Xcath Incorporated, a privately held neurovascular robotics company, he held similar positions at Optiscan Biomedical, and Myoscience.

“We continue to make progress on impacting the future of minimally invasive robotic surgery and the operating room ecosystem,” he said. “Our technical partnerships, our relationships with surgeons and the dedication of our employees support our efforts in submitting an IDE application, designing forthcoming clinical trials and planning our commercialization strategy for the U.S. market.”

Titan Medical is a medical device company which focuses on enhancing robotic assisted surgery using innovative technology through a single access point. The company is headquartered in Toronto, Ontario, with operations in Chapel Hill, North Carolina. 

Titan Medical Inc. (TMD) was down 6.85 per cent, trading at C$0.68 per share at 12:20 pm ET.


More From The Market Herald

" Lumiera Health (TSXV:NHP) partners with natural health industry leader

Lumiera Health (NHP) has signed an MoU to explore a strategic partnership with one of Quebec’s leaders in the natural health industry.

" No pain, no blood: BETTER Type 2 diabetes testing is coming to market

Over the past two years, reporting on the Covid-19 pandemic has dominated media airwaves.

" Reunion (TSX:REUN) appoints Greg Mayes as President and CEO

Reunion Neuroscience (REUN) (formerly Field Trip Health Ltd.) has appointed Greg Mayes as President and Chief Executive Officer.

" Microbix Biosystems (TSX:MBX) announces NCIB

Microbix Biosystems (MBX) has announced a Normal Course Issuer Bid for the repurchase and cancellation of outstanding common shares.